This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Irinotecan and Flavopiridol in Treating Patients With Advanced Liver Cancer

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: July 8, 2004
Last updated: June 21, 2013
Last verified: May 2005

RATIONALE: Drugs used in chemotherapy, such as irinotecan and flavopiridol, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving irinotecan together with flavopiridol works in treating patients with advanced liver cancer.

Condition Intervention Phase
Liver Cancer Drug: alvocidib Drug: irinotecan hydrochloride Phase 2

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Non-Randomized Phase II Study of Sequential Irinotecan (CPT-11) And Flavopiridol In Patients With Advanced Hepatoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: June 2004
Study Completion Date: July 2006
Detailed Description:



  • Determine the time to progression in patients with advanced hepatocellular carcinoma treated with irinotecan and flavopiridol.


  • Determine the response rate and overall survival in patients treated with this regimen.
  • Determine the toxicity of this regimen in these patients.

OUTLINE: This is an open-label, non-randomized study.

Patients receive irinotecan IV over 30 minutes and flavopiridol IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 16-32 patients will be accrued for this study within 2 years.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically or cytologically confirmed hepatocellular carcinoma

    • Advanced disease
  • Measurable disease

    • At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
  • Prior local therapy (e.g., surgery, hepatic arterial embolization, radiofrequency ablation, or cryoablation) allowed provided therapy was completed ≥ 8 weeks before study entry AND ≥ 1 of the following conditions are met:

    • Target lesion was not subjected to local therapy
    • 25% increase in the size of target lesion within the field of prior local therapy

      • Lesions treated with external beam radiotherapy are not acceptable as target lesions
  • Child-Pugh class A or B status if liver cirrhosis is present

    • Score 7 or 8 only
  • No known brain metastases



  • 18 and over

Performance status

  • Karnofsky 70-100%

Life expectancy

  • Not specified


  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 75,000/mm^3
  • WBC ≥ 3,000/mm^3


  • See Disease Characteristics
  • AST and ALT ≤ 2.5 times upper limit of normal
  • Bilirubin ≤ 1.5 mg/dL


  • Creatinine normal OR
  • Creatinine clearance ≥ 60 mL/min


  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No deep vein thrombosis within the past 6 months

    • Patients maintained on anticoagulation therapy for an event that occurred more than 6 months ago are eligible
  • No myocardial infarction within the past 6 months
  • No cardiac arrhythmia within the past 6 months

    • Rate-controlled atrial fibrillation allowed if stable for at least 6 months


  • No pulmonary embolus within the past 6 months

    • Patients maintained on anticoagulation therapy for an event that occurred more than 6 months ago are eligible


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months after study participation
  • No prior allergic reaction attributed to compounds of similar chemical or biological composition to flavopiridol or irinotecan
  • No clinically significant gastrointestinal bleeding requiring hospitalization within the past month
  • No active or ongoing infection
  • No psychiatric illness or social situation that would preclude study compliance
  • No other uncontrolled illness
  • No other malignancy within the past 3 years except carcinoma in situ of the cervix, adequately treated basal cell skin cancer, or superficial bladder tumors [Ta, Tis, or T1]


Biologic therapy

  • No prior systemic biologic therapy


  • No prior systemic chemotherapy for hepatocellular carcinoma
  • No other concurrent chemotherapy

Endocrine therapy

  • Not specified


  • See Disease Characteristics


  • See Disease Characteristics
  • No prior organ allograft


  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No concurrent vitamins, antioxidants, or herbal preparations and supplements

    • Single-tablet multivitamin allowed
  • No other concurrent investigational agents
  • No other concurrent anticancer agents or therapies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00087282

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Ghassan Abou-Alfa, MD Memorial Sloan Kettering Cancer Center
Principal Investigator: Gary K. Schwartz, MD Memorial Sloan Kettering Cancer Center
  More Information Identifier: NCT00087282     History of Changes
Other Study ID Numbers: CDR0000373877
Study First Received: July 8, 2004
Last Updated: June 21, 2013

Keywords provided by National Cancer Institute (NCI):
adult primary hepatocellular carcinoma
advanced adult primary liver cancer
recurrent adult primary liver cancer

Additional relevant MeSH terms:
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Growth Inhibitors
Growth Substances
Physiological Effects of Drugs
Protein Kinase Inhibitors processed this record on August 18, 2017